<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761007</url>
  </required_header>
  <id_info>
    <org_study_id>NAK 03</org_study_id>
    <secondary_id>2008-000214-71</secondary_id>
    <nct_id>NCT00761007</nct_id>
  </id_info>
  <brief_title>Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)</brief_title>
  <acronym>IRIS</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Effect of a 4-week Treatment With Oral Doses of Ibodutant (Code: MEN15596) in Irritable Bowel Syndrome (IBS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant
      (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable Bowel Syndrome (IBS) is a functional disorder characterised by chronic or recurrent
      abdominal pain or discomfort associated with altered bowel habits. This trial aims to
      evaluate the efficacy of Ibodutant in improvement of IBS symptoms through a daily oral
      administration, testing three dosages or placebo in IBS patients for 4-weeks. In each
      patient, the experimental clinical phase encompasses a screening/ 2-week run-in period (no
      study medication), followed by a 4-weeks treatment period and a 2-weeks treatment withdrawal
      period, for total study duration of 8 weeks in each patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response of Overall IBS Symptom Relief - 50% Rule</measure>
    <time_frame>Four weeks</time_frame>
    <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 2/4 weeks (50% rule)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of Overall IBS Symptom Relief - 75% Rule</measure>
    <time_frame>Four weeks</time_frame>
    <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS With Diarrhea (IBS-D) - 75% Rule</measure>
    <time_frame>Four weeks</time_frame>
    <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">554</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Ibodutant 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibodutant 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibodutant 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibodutant</intervention_name>
    <description>Oral tablet, dose level 1 (10 mg), once daily</description>
    <arm_group_label>Ibodutant 10 mg</arm_group_label>
    <other_name>Code: MEN 15596</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibodutant</intervention_name>
    <description>Oral tablet, dose level 2 (30 mg), once daily</description>
    <arm_group_label>Ibodutant 30 mg</arm_group_label>
    <other_name>Code: MEN 15596</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibodutant</intervention_name>
    <description>Oral tablet, dose level 3 (60 mg), once daily</description>
    <arm_group_label>Ibodutant 60 mg</arm_group_label>
    <other_name>Code: MEN 15596</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet matching the three dose levels of ibodutant, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 18 - 70 years.

          2. Clinical diagnosis of IBS .

          3. For patients older than 50 years or patients with positive family history of
             colorectal cancer: normal results from colonoscopy or flexible sigmoidoscopy.

          4. Use of appropriate contraceptive methods.

          5. Normal physical examination or without clinically relevant abnormalities.

        Exclusion Criteria:

          1. Patients with organic abnormalities of the gastro-intestinal tract including history
             of colonic or major abdominal surgery, current or previous diagnosis of neoplasia,
             inflammatory bowel diseases, symptomatic gallbladder stone disease,
             diverticulosis/diverticulitis, ectopic endometriosis.

          2. History of gluten enteropathy.

          3. Lactose intolerance as assessed by response to diet

          4. Diagnosis of ova or parasites, or occult blood in the stool in the previous 6 months.

          5. Previous diagnosis of Diabetes Mellitus (either type 1 or 2)

          6. Unstable medical condition.

          7. Concomitant medication within 7 days prior to screening with drugs known to interfere
             with gastro-intestinal motility and sensitivity.

          8. Pregnancy or breastfeeding.

          9. Patient not able to understand or collaborate throughout the study.

         10. Participation in other clinical trials in the previous 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tack, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gastroenterology, University Hospital Katholieke Universiteit Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical and Basic Research (CCBR)</name>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Diseases Center &quot;Gastro&quot;</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Outpatient clinic #3&quot; of President's Management Department of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academy of Medical Science of Ukraine</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Centre</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>September 8, 2010</results_first_submitted>
  <results_first_submitted_qc>September 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2010</results_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Bowel disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled 15/07/2008, last subject observed 18/02/2009, at 60 study centres in 9 European countries (Denmark, Germany, Italy, Latvia, Russia, Slovak Republic, Spain, United Kingdom, and Ukraine.</recruitment_details>
      <pre_assignment_details>Subjects underwent a 2-week screening period to meet inclusion/exclusion criteria and were subsequently randomised.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibodutant 10 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="P2">
          <title>Ibodutant 30 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="P3">
          <title>Ibodutant 60 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>oral tablet, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety (&gt;=1 Dose of Study Medication)</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT (&gt;= 1 Assessment Post-Randomisation)</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibodutant 10 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B2">
          <title>Ibodutant 30 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B3">
          <title>Ibodutant 60 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="136"/>
            <count group_id="B5" value="544"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="13.43"/>
                    <measurement group_id="B2" value="45.0" spread="12.66"/>
                    <measurement group_id="B3" value="44.4" spread="12.97"/>
                    <measurement group_id="B4" value="43.7" spread="13.73"/>
                    <measurement group_id="B5" value="44.2" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IBS-Subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IBS-Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IBS-Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IBS-Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IBS-Unsubtyped</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response of Overall IBS Symptom Relief - 50% Rule</title>
        <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 2/4 weeks (50% rule)</description>
        <time_frame>Four weeks</time_frame>
        <population>Intention-to-Treat (N=544)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 30 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 60 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Overall IBS Symptom Relief - 50% Rule</title>
          <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 2/4 weeks (50% rule)</description>
          <population>Intention-to-Treat (N=544)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response of Overall IBS Symptom Relief - 75% Rule</title>
        <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
        <time_frame>Four weeks</time_frame>
        <population>Intention-to-Treat (N=544)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 30 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 60 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Overall IBS Symptom Relief - 75% Rule</title>
          <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
          <population>Intention-to-Treat (N=544)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS-Diarrhea (IBS-D) and Pain at Baseline - 75% Rule</title>
        <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
        <time_frame>Four weeks</time_frame>
        <population>Intention-to-treat subgroup of patients with IBS-D and baseline pain score&gt;1 (in a 5-point scale ranging from 0=no pain to 4=very severe) (N=189)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 30 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 60 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS-Diarrhea (IBS-D) and Pain at Baseline - 75% Rule</title>
          <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
          <population>Intention-to-treat subgroup of patients with IBS-D and baseline pain score&gt;1 (in a 5-point scale ranging from 0=no pain to 4=very severe) (N=189)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS With Diarrhea (IBS-D) - 75% Rule</title>
        <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
        <time_frame>Four weeks</time_frame>
        <population>Intention-to-treat (ITT) subgroup of patients with IBS-D (N=234)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 30 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 60 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS With Diarrhea (IBS-D) - 75% Rule</title>
          <description>Weekly binary question (yes/no): &quot;Did you have satisfactory relief of your overall IBS symptoms since the last visit?&quot;
Responder: report of satisfactory overall IBS symptom relief = &quot;Yes&quot; 3/4 weeks (75% rule)</description>
          <population>Intention-to-treat (ITT) subgroup of patients with IBS-D (N=234)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Four weeks</time_frame>
      <desc>Analysed for the Safety Population (all patients who took at least one dose of study medication, N=551)</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibodutant 10 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="E2">
          <title>Ibodutant 30 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="E3">
          <title>Ibodutant 60 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>oral tablet, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="12" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Capriati MD PhD, Clinical Research Director</name_or_title>
      <organization>Menarini Group- Clinical Research</organization>
      <phone>+39 055 5680 ext 9933</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

